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impact on mortality, when the patient did not receive thmmbolytic treatment. 
Patients who received thrombolytic treatment had benefit of early admission 
and thrombelysis as long as three years pest-AML 
~ Clinical Charecfarletics Predictors of Mortality as 
in Poet-Myocardial infarction Patients 
R.T. van Domburg, J.W. Deckers, A.J. Azar, P.RM.M. van Bergen, 
J.J.C. Jonkar. Univers#y HoSl~ita/ Dijkzigt and Erasmus University 
Rotterdam, The Netherlands 
We investigated the relative contribution of variables from the history of the 
patient at admission and additional information obtained uring hospitaliza- 
tion in 3404 pest-myocardial infarction patients (80% male). Included were 
patients with at least two of the following criteria: persistent chestpain typical 
for MI, at least twice the normal enzyme fimif and ST-T changes on the 
electrocardiogram. Excluded were patients with indication for oral anticoag- 
ulant treatment, increased bleeding tendency, cardiomyopathy, anticipated 
revasculadsation, malignant disease, mental disorder and pregnancy. 
Patients were admitted from 1986 till 1992. After a median follow-up of 
3 years (0.5-6 years) 359 patients had died. In 77%, the cause of death 
was cardiovascular. Data on infarct size were not available. Multivariate Cox 
regression was performed on both history and hospitalization variables. 
HR and 95% CI History History + hospitalization 
Age/year 1.07 1.06--1.08 1.07 1.06-1.08 
Diabetes 1.39 1.01-1.91 
History of angina 1.33 1.04-1.71 
Previous infarction 1.68 1.26-2.23 1.62 1.22-2.15 
Hospitalization History + hospitalization 
Heartha'~JureJnhospJte] 2.71 1.97-3.72 2.05 1.80-2.80 
VTNF > 24 hour 1.50 0.90-2,48 1,57 0.97-2.55 
Thrombolysis 0.48 0.35-0.67 0.74 0.54--1.00 
Beta-blocker 0.60 0.48-0,76 0.69 0.55-0.63 
Prediction of outcome improved when additional information was added 
to the model. Relative simple clinical characteristics, as shown in the table, 
contributed significant in the prediction of mortality. 
These data illustrate the importance of an integrated approach to outcome 
prediction in pest-myocardial infarction patients and provide a minimum set 
of variables that should be included when the relative worth of additional 
prognostic tests is considered in these patients. 
I-~"(~"9.-9-0-'1 Left Ventrioular Functional Detsrminants o f  2 Yea r 
Mortality Following Acute Myocardial Infarction 
Conor F. Lundergan, Jonathan S. Reiner. Ailed M. Ross. George 
Washington Universi~, Washington, D.C. 
Numerous indices of global and regional left ventricular function have been 
used to stratify early or intermediate t rm mortality prognosis following acute 
myocardial infarction (AMI). In a large and unique population, the GUSTO-1 
Angiographlc Trial, 2 year mortality data is now complete with only 115/2431 
(4.7%) patients lost to follow-up. We determined the relative contribution of 
venfficulographic indices obtained within 5-7 days of the Index AMI to 2 
year mortality by multivariate logistic regression analysis in 1808 patients 
with complete anglogrophic and 2 year mortality data sets. Angiogrophlc 
variables included ejection fraction (El=), end systolic volume index (ESVI), 
end-diastolic volume index (EDVI), regional extent of infarction (# of chords) 
and regional infarct severity (SDIchord). Variables were entered into the mul- 
tivariate model in a stepwlsa manner eflective of their blolo"dc significance. 
EF, ESVI, EDVI, regional extent and severity of Infarctior, ,ere significant 
determinants of 2 year mortality by univariate analysis (all ~, < 0.0001). In- 
dependent determinants of 2 year mortality were: (RR = relative risk; CI = 
confidence limits) 
RR 95% CI 
EF (< 40, > 40) 2.8 (1.8,4,3) 
# Chords (< 16, • 16) 1.9 (1.3, 3.0) 
ES,,Vi (< 34, > 34) 1.8 (1.2, 2.7) 
Conclusions: 1. This prospective study illustrates the relative contribution 
of global and regional indices of ventricular function to long term mortality 
following AMI. 2, Global ventficular function and the extent of regional van- 
tricular dysfunction i  the infarct zone are each potent independent predictors 
of long term (2 year) prognosis in AML 
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[ 1010-1091 Predictors and Late Sequelae of Distal 
Embolizetion In Patients With Cmetlne Klnsse 
Elevation Following Elective PTCA 
Thomas Q, Kong, Sheridan N. Meyero, Mlchele A, Parker, Michael D. EIliott, 
Charles J. Davldson, Northwestern University Medical School, Chicago, IL 
We have previously shown that distal embolizatton (DE) at PTCA frequently 
results in croatine kinase (CK) elevation (99% incidence). To identify predic- 
tors of distal embolization, anglographlc data from patients with CK elevation 
after elective PTCA using DCA, TEC, or balloon were evaluated. Logistic 
regression analysis was employed to determine device and lesion character- 
Istics as well as their interactions which were predictive of distal embelization. 
Results: Elective PTCA was performed on 503 lesions in 237 patients 
who developed CK elevation after PTCA (62 :E 11 yrs; 70% male; 2.1 :E 1.3 
lesions per patient). DE was observed following treatment of 75 lesions. 
Un.. ~adate DE No DE p Multivariate p 
TEc (%) 32 9 <0.00001 TEC O.O0t 
Thrombus (%) 32 10 <0.00001 DGA 0,006 
DCA (%) 31 11 <0.00001 Thrombus 0.0003 
Initial stenosis (~.) 91 ± 9 86 ± 13 <0.01 
Total occlusion (%) 15 7 < 0.04 
Init. TIMI flow < 3 (%) 40 24 <0,03 
Vein graft PTCA (%) 31 10 <0.00001 
At 3.5 -4- 2.3 years follow-up, cardiac death occurred in 15/69 (22=/0) of 
patients with vs. 19/168 (11%) without DE (p < 0.04). 
Conclusions: 1) The use of DCA or TEC is strongly associated with distal 
embolization. 2) Thrombus is the only angiographic lesion characteristic that 
is independently associated with DE. 3) DE is predictive of excessive late 
cardiac death. 
I 1010-1101 Vascal•r Access Site Complications During 
Angloplesty With Glycoprotein Ilbllla Receptor 
mhlbition In the IMPACT II Trial 
James Blankenship, Jeffrey Mandak, Frank Aguirre, Scott D. Berkowitz, 
lan GIIchrist, Khaltd Sheikh, John Griffin, Michael Mclvor, Jon Rasar, 
Bonnie Weiner, John George, David Tally, Gerald "rimmis, Michael Uncoff, 
James Tcheng, Robert Califl, Eric Topoi for the IMPACT II Investigators. 
Gelsinger Medical Center, Danviffe, PA 
Glycoprotein lib/Ilia receptor inhibition during coronary interventions lint) has 
been associated with excess vascular access site (VAS) complications. We 
assessed VAS complications from tot with a new glycoprotsin lib/ilia receptor 
inhibitor (Integrolin) in the IMPACT II trial. 4010 patients (pts) undergoing Int 
were randomized to placebo vs bolus/low dose 24 hour Infusion vs bolus/high 
dose 24 hour infusion of Integrolin. Heperin during Int was weight-adjusted 
and was stopped 4 hrs before sheaths were pulled. 
Results: Vascular surgical repair was rare (1"/o) and did not correlate with 
treatment, artedat sheath size, time to sheath removal, or use of a venous 
sheath. 79% of all moderate-severe bleeds occurred at the VAS. Moderote- 
severe VAS bleeding occurred in more Integrolin-treated pts (8,8% vs 5.3% 
placebo pts, p =, 0.0001), pts with venous sheath (8.4% vs 5.7=/0 no sheath, p 
= 0.002) and pts with sheath removed > 12 h (9.6% vs 5.6% sheath >_. 12 h, 
p ,= 0.0001). Procedural ACT was higher (398 ± 142 vs 388 + 185 seconds, 
p = 0,02) In modemmte-severo VAS bleed pts than in none/minor VAS bleed 
pts, A trend toward more rnodemta-severo VAS bleeding was observed with 
larger sheath size (p = 0,08). 
Conclusions: 1) Integrciin increases moderata-severo VAS bleeding. 2) 
VAS bleeding may be reduced by early sheath removal and avoiding venous 
sheaths. 3) Early sheath removal during inhibition of platelet aggregation by 
Integrciln is safe and may be a preferred strategy. 
11010-111 I Reuse of FrCA Catheters Is Not Associated With 
" Increased In-hospital Complications 
Kocn-Hou Mak, Mark J, Eisenberg, Sylvaln Plants, Bradley H, Strauss, 
Kdstopher L Aphead, Eric J. TopoL The Cleveland Clinic Foundation, 
Cleveland, OH 
Although catheter ouse may reduce cost, a recent prospective study in 693 
patients compared a center that rouses PTCA catheters with a center that 
uses only new catheters uggested that potential savings may be offset by 
increased in-hospital complications. To examine this issue, we roanalyzed 
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the data using a multivariate logistic regression model to control for dilfer- 
encos in patients' clinical charactedstica for the occurrence of the composite 
endpolnt, consisting of death, myocardial infarction, abrupt vessel closure, 
and coronary artery bypass surgery, The mean age was 60 (SD ± 11) years, 
with 72% men, and 46.2% received reused catheters. Composite ndpoInt 
occurred In 57 patients, with ACC/AHA lesion type, angina class, procedure 
time, and residual stsoosls as predictors for outcome. 
Odds Ratio 95% Confidence tnlarval 
Catheter Reuse 0.59 0.31-1.14 
A~e 1.00 0.97--1.O3 
Male 0,57 0.29-1.14 
Angina class 1.95 1.23-8.11 
ACCIAHA lesion type 2.30 1.03-5.11 
Rssi¢lual stsnosis 1.03 1.01-1.04 
Procedure 1~me 1.02 1.02-I.03 
We ooncluds that, after controlling for baseline clinical and angingrephlo 
characteristlos, reuse of PTCA catheters did not appear to be associated 
with an increase in in-hospital complications. 
1 1010"1!2 1 Vorlebility in Balloon Sizing During Routine 
PTCA ~ Quantitative Coronary and Ultrasound 
Analysis 
Grogs W. Stone, Fred G. St. Goat, Tom Unnemeier, Helen Sheahan, John 
McB. Hedgson. El Camino Hospital, Mountain View, CA: University 
Hospitals of Cleveland, Cleveland, OH 
A balloon:artery (b:a) ratio of 1.0-1.1 is considered optimal for the podor- 
menco of PTCA. To assess variability of balloon sizing, coronaw angiography 
and ultrasound images from 48 lesions in 47 pts undergoing PTCA by 3 expe- 
rienced operators were analyzed by an independent core lab. QCA measured 
b:a ratios at peak preSSure inflation were determined. 
Results: The maximal b:a ratio was 1.0-1.1 in only 14 Isns (29%); the b:a 
ratio was < 1.0 in 18 Isos (38%) end > 1.1 in 16 tsos (33%), ranging from 
036 to 1.44. Implications of the variability in balloon sizing appear below: 
Ba[loon:arteryretlo . < 1.0 1.0-1.1 > 1.1 p 
Peak pressure (aim.) 7.2 4-1.4 7.3 4-1.9 6.4 4-1.2 NS 
QCA ref. seg. ella. (ram) 2.94-0.3 2.5:1:0.4 2.24-0.3 0.001 
QCA die. %stenos~s pro 574-14% 63 ~: 13% 65±10% NS 
QCA die. %slenosls post 31 4-13% 354-11% 194-23% 0.03 
Adia. %stenosts pro.post -35 4-17% -29 ~- 15% -45 4- 24% 0.07 
81sn MLD(mm) pro-post 1.0 4- 0.5 0.9 :t: 0.4 1.2 4- 0.7 NS 
D,~sect~an score >_ typeB 1 (';~| 3 (17%) 4(25%) NS 
ICUS area %stenosis post 48 4-19% 46 4-17% 43:1:14% NS 
ICUS plaque burden post 77 4- 7% 80 4-10% 76 ± 9% NS 
Conclusions: Contrary to expectations, the balloons that experienced op- 
eretors choose result in markedly variable b:a ratios dunng PTCA, with 
relatively larger balloons used in smaller vessels. When safely applied, a b:a 
ratio of > 1.1 results in a lower angiographic residual stenasis. By ICUS, 
however, a large residual plaque burden is present after PTCA independent 
of b:a ratio. 
1 1010-1131 Rapid Assessment of Platefat InhiblUon Usleg a 
ModiBad Whole Blood Aggregometer 
(Aggrsstat") in PTCA Patients Receiving 
ReoPro 
Maw Ann Mascalll, Ellen Lance, Sabine Mack, Hadan Weisman, 
Thomas Schalble, Robert Jordan. Centocor, Inc., Maivem, PA 
ReaP~ TM pOtently blocks GPflb/llla, inhibits platelet aggregation and reduces 
Ischemlo complications inhigh dsk PTCA patients. Currently, no bedside taste 
are available for rapid and accurate measurement of plalalet inhibition dudng 
and following ReaPre TM treatment. To address this need, a bedside device 
(Aggrastat') that measures platelet aggregation in whole blood using elec- 
trical impedance was developed and compared in 12 patients to standard 
measurement using light transmittance through platelet rich plasma (PRP). 
All patients received ReaPro~'; 0.25 mg/kg bolus plus a 10 pg/mln infusion 
for 12 hr. inhibition of platalet aggregation in whole blood assessed by the 
Aggrestat" yielded similar results to aggregation in PRP using light trans- 
mlttanca and showed the same close correletion with GPIIb/llla blockade 
(results are mean .4- SD): 
%GPllb/llla % Inhibition of Aggregation 
Blockade Agg tat TM PRP Agg~. 
15 rain post-ReoPre~ bolus 96~1.6 ~4-4.2 974-2.4 
2 h post-ReoPre" bolus 92 4- 2.7 88 4- 7.5 97 :l: 2.2 
12 h post-ReoPre TM infusion 66 d: 7.5 69 4.13 63 4- 20 
These results indicate that the Aggrestat TM is a practical method for rapid 
measurement (within 10 minutes of blood draw) of plalelet function at the 
bedside dudng and following anti-platelet therapy. 
[ ~  Eight Year, Long Term Outc3me After PTCA: 
Factors Associated With Adverse Events. The 
NHLBI PTCA Registry 
David R. Holmes, Kathedne Delta, Wan I.in Web, Spencer King, 
Sheryl Kelssy. Mayo Clinic, Rochester, MN 
Risk factors assodated with poor outcome during long term follow up after 
percutaneous translumlnal coronary angioplasty (PTCA) remain poorly de- 
fined. In the NHLBI PTCA Registry, there is now 8 year follow up of 1759 pts 
who had initially successful PTCA. A multivariate model was used and 24 
clinical and angingraphlo factors including baseline demographics, present- 
ing symptoms, left ventdcLitar function and extent of coronary artery disease 
were evaluated to determine those factors assodated with a hierarchical 8
year adverse endpoint of death (D), death and myocardial infarction (Mi), 
and death, myocardial infarction and coronary surgery (CABG). Only factors 
with p < 0.001 were considered. 
Factor D D/MI D/MI/CABG 
RR" CI t RR CI RR Cl RR CI RR CI 
Hx ~CHF 2.65 (1.78, 3~94) 2.22 (1.57, 3.13) 2.17 (1.53, 3 .~ 
Severe non 2.56 (130, 3.85) 1.91 (1.34, 2.74) -
cardiac disease 
Diabetes 2.04 (1.48,2.81) .78 (1.38,2.31) .90 (1.46,2.47 
> 65 yre 1.98 (1.50, 2.62) -
MVD, 1.79 (132, 2.36) 1.58 (1.25,1.98) 1.58 (1.34, 2.16 
"RR = relative rlsk, tC! = 95% confidence fnten~ 
"MVD = multivessel disease, fCHF = congestive heart failure 
Easily recognizable baseline dsk factors are the factors most closely asso- 
dated with long term (8 year) adverse prognosis following PTCA irrespective 
of whether death, death and MI, or death MI and CABG are used as end- 
points; of these favors, a history of CHF at baseline is the most powerful. 
I 1 010-115 1 Pedprocedurs Myoca~llal Infarction R~tes in the 
Bypass Angleplesty Revassularization 
Investigation (BARI) 
Bernard R. Chairman, Alice K. Jacobe, E. Magn~ Ohman, Ronald J. Krone, 
Charles J. Mullany, George Sopko. thor Gussak, Kim Suifon-'ryrrell, Allan 
D. Rosen, and the BARI Invastigators. St. Louis University School of 
Medicine, St. louis, MO 
The Bypass Angloplasty Revascularization I vestigation (BARI) examined 
the hypothesis that an initial revascutarization strategy of percutaneous trans- 
luminal coronary angioplasty (PTCA) compared to coronary artery bypass 
greft (CABG) in pts with multivassel coronary disease does not compro- 
mise clinicel outCome during 5 year follow-up. We report he incident rate of 
proosdere-related myocardial infarction (MI), an event w~ a potential nega- 
tive impact on long-tom1 sunn'val, In each treatment group. Between August, 
1988 and August, 1991,914 and 915 pts were randomly assigned to PTCA or 
CABG. The MI event rates were examined in a pdod determined subgroups 
of unstable angina (69% of the population), severe chronic stable angina 
(16%), and mild or no angina with severe Ischsmia on noninvasive tasting 
(15%); and in patient subsets stratified by number of diseased vessels and 
left vantdcular ejection fraction; and in presence or absence of proximal left 
anterior descending stanosls > 50=/o, hypertension, diabetes, and congestive 
heart failure. Ascertainment ofMI was based on asfial ECG analysis, cardiac 
enzyme data, and dinloal history, and events were dassitied at St, Louis 
University Core laboratory. The new appearance of a 2 grade Minnesota 
code Q-wave progression defined a Q-weve MI event when it occurred < 96 
hours post procedure. If the event occurred > 96 hours postprocodure, MI 
was defined if a 2 grade Minnesota code Q-wove progression occurred; or if 
cardiac enzymes were abnomml in the presence of a new left bundle brenoh 
block; or if cardiac enzymes were abnormal in the wasenco of cheat pain 
or worsening ST-T wove abnormalities. The incident rate of Q-wave MI was 
compared within 96 hours post procedure and 3 months post procedure. The 
periprocodure Mi rates associated with the Index randomization and sub- 
sequent revascutadzation procedures will be presented for both treatment 
strategies. 
